News
Public · Published
Piramal Pharma looks to a 'significantly stronger' second half of the year: Nandini Piramal
Piramal Pharma raised its annual growth guidance from low to mid-teens to 19–20 per cent, chairperson Nandini Piramal said, expecting a significantly stronger second half. Second-quarter net profit was ₹5 crore versus a ₹99 crore loss a year earlier, and revenue rose 28 per cent to ₹2,617 crore.
Published:
Updated:
What happened
Piramal Pharma raised its annual growth guidance from low to mid-teens to 19–20 per cent, chairperson Nandini Piramal said, expecting a significantly stronger second half. Second-quarter net profit was ₹5 crore versus a ₹99 crore loss a year earlier, and revenue rose 28 per cent to ₹2,617 crore.
Confirmed
Global impact / market context
Because the company says it operates largely with fixed costs, which are expenses that stay roughly the same regardless of sales volume, higher revenue can flow through to profit. That means each extra sale adds more to the bottom line, so the raised guidance implies stronger profit per sale, not just top-line growth.
Analyst inference
The stock was up over 17 per cent at ₹233.70 on the BSE at 2 pm Wednesday, showing investors quickly repriced shares on the guidance increase and the swing to profit. Broad-based growth across CDMO, which means contract development and manufacturing for other drugmakers, plus generics and consumer healthcare, and a healthy order book support the second-half expectation.
Analyst inference
What to watch
- Watch whether second-half revenue actually reaches the upper end of 19–20 per cent growth, since that outcome underpins the raised guidance and the expectation that higher sales convert into higher profitability. Confirmed
- Track order inflows, including request-for-proposal activity, which means customer bids for contract work, because the article links improved inflows and a healthy order book to confidence in the stronger second half. Proposed
- Monitor whether fixed costs stay flat as revenue grows; if they do, profit should rise faster than sales, but any cost increase would weaken that transmission and challenge the profitability expectation. Analyst inference
Evidence
- Original source link unavailable